3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
4
Phase 2
1
Phase 1/2
1
Status
Withdrawn
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Dermatologic
1
Conditions
Ovarian Neoplasms
5
Neoplasms
5
Carcinoma, Non-Small-Cell Lung
5
Prostatic Neoplasms
4
Glioblastoma
4
Carcinoma, Renal Cell
4
Sarcoma, Alveolar Soft Part
3
Sarcoma
3
Gliosarcoma
3
Fallopian Tube Neoplasms
3
Carcinoma, Hepatocellular
3
Breast Neoplasms
3
Uveal Melanoma
2
Uterine Cervical Neoplasms
2
Solitary Fibrous Tumor, Pleural
2
Mesothelioma, Malignant
2
Colorectal Neoplasms
2
Carcinosarcoma
2
Carcinoma, Ovarian Epithelial
2
Brain Neoplasms
2
Triple Negative Breast Neoplasms
1
Tongue Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Small Cell Lung Carcinoma
1
Salivary Gland Neoplasms
1
Rectal Neoplasms
1
Pleural Effusion, Malignant
1
Neurofibromatosis 1
1
Neurofibroma, Plexiform
1
Neoplasm Metastasis
1
Interventions
Oxaliplatin
67
Capecitabine
60
Fluorouracil
58
Bevacizumab
54
Gemcitabine
51
Paclitaxel
50
Leucovorin
50
Irinotecan
40
Docetaxel
39
Carboplatin
39
Cisplatin
38
pembrolizumab
37
Nivolumab
37
Cetuximab
35
Sunitinib
25
Trastuzumab
24
Radiosurgery
24
Radiotherapy
21
Doxorubicin
21
Cyclophosphamide
21
Panitumumab
20
Drug Therapy
19
Pemetrexed
18
Everolimus
18
Sorafenib
17
Interleukin-2
16
Fulvestrant
16
Albumin-Bound Paclitaxel
16
atezolizumab
15
Erlotinib Hydrochloride
15
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2
×
Neoplasm Metastasis
×
cediranib
×
Clear all
NCT04184518
2020-06-02
CEDUVEAL-M
Grupo Español Multidisciplinar de Melanoma
Phase 2
Withdrawn